RxDoctor Payments Data

Frank Almeida, MD

Internal Medicine · Manasquan, NJNPI 1518979541

Payments from drug & device makers

$14,645in general payments, 2019–2025

Across 1,087 payments — averaging $13.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Pfizer$898
  • Lilly USA, LLC$860
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$14,633100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk156$2,085
AbbVie(2 entities)129$1,518
AstraZeneca86$1,419
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC79$1,137
Pfizer114$898
Lilly USA, LLC65$860
Amgen59$782
GSK56$780
Bayer37$633
Boehringer Ingelheim37$518
Johnson & Johnson17$266
Merck18$244
Kowa Pharmaceuticals America, Inc.17$236
Teva Pharmaceuticals USA, Inc.15$224
Amarin Pharma, Inc.15$210
Abbott12$209
Takeda Pharmaceuticals U.S.A., Inc.18$193
Boston Scientific6$168
Exact Sciences8$163
E.r. Squibb & Sons, L.L.C.11$152
Daiichi Sankyo Inc.10$145
Astellas Pharma US Inc10$138
Sanofi-aventis U.S. LLC9$136
Optinose US, Inc.7$101
Biohaven Pharmaceutical Holding Company Ltd.6$86
Tolmar, Inc.5$84
Novartis5$81
Esperion Therapeutics, Inc.6$81
Regeneron Healthcare Solutions, Inc.5$80
Genentech USA, Inc.6$77
Almatica Pharma LLC4$64
Arbor Pharmaceuticals, Inc.4$60
Hikma Pharmaceuticals USA4$58
Sanofi Pasteur Inc.3$46
Bausch Health US, LLC3$45
Topcon Healthcare Solutions, Inc.1$43
Xeris Pharmaceuticals, Inc.3$43
Lundbeck LLC3$43
Jazz Pharmaceuticals Inc.3$42
Radius Health, Inc.3$42
Eisai Inc.3$40
Antares Pharma, Inc.2$34
Aytu Biopharma, Inc.2$30
Axsome Therapeutics, Inc.2$30
Phathom Pharmaceuticals, Inc.3$29
Currax Pharmaceuticals LLC2$28
Seqirus USA Inc2$28
Biohaven Pharmaceuticals, Inc.2$27
Insulet Corporation1$24
Harmony Biosciences LLC1$19
Vanda Pharmaceuticals Inc.1$16
Halozyme Inc1$16
ARS Pharmaceuticals Operations, Inc.1$15
Otsuka America Pharmaceutical, Inc.1$15
Collegium Pharmaceutical, Inc.1$14
Acerus Pharmaceuticals Corporation1$14
Acella Pharmaceuticals, LLC1$14
Eyevance Pharmaceuticals LLC1$14
Vertical Pharmaceuticals, LLC1$13
Nalpropion Pharmaceuticals LLC1$13

How this compares

$14,645 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$116,082
Medicare patients
432
Services billed
1,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide82$90,020
FarxigaDapagliflozin Propanediol50$47,599
OtezlaApremilast12$46,081
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$43,202
JardianceEmpagliflozin27$32,539
JanuviaSitagliptin Phosphate23$29,616
OzempicSemaglutide20$23,947
EliquisApixaban23$21,550
XareltoRivaroxaban22$21,087
Janumet XrSitagliptin Phos/Metformin Hcl25$18,777
JanumetSitagliptin Phos/Metformin Hcl13$18,474
TradjentaLinagliptin12$17,335
Nucynta ErTapentadol Hcl11$15,712
Xigduo XrDapaglifloz Propaned/Metformin13$13,461
EntrestoSacubitril/Valsartan14$13,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$860$90,02082 claims
MerckJanuvia, Janumet Xr, Janumet$244$66,86761 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$518$55,08350 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,419$54,27161 claims
AmgenOtezla$782$46,08112 claims
GSKTrelegy Ellipta$780$43,20251 claims
Novo NordiskOzempic$2,085$23,94720 claims
PfizerEliquis$898$21,55023 claims
Johnson & JohnsonXarelto$266$21,08722 claims
Collegium Pharmaceutical, Inc.Nucynta Er$14$15,71211 claims
NovartisEntresto$81$13,00714 claims
AbbVieSynthroid$1,518$3,51446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Manasquan

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →